Necrosulfonamide

Catalog No.S8251 Batch:S825103

Print

Technical Data

Formula

C18H15N5O6S2
Molecular Weight 461.47 CAS No. 1360614-48-7
Solubility (25°C)* In vitro DMSO 92 mg/mL (199.36 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Homogeneous suspension for Oral and Intraperitoneal Injection. Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Necrosulfonamide is a very specific and potent necrosis inhibitor and blocks mixed lineage kinase domain-like protein (MLKL).
Targets
necrosis(MLKL) [1]
In vitro

Necrosulfonamide inhibits MLKL-mediated Necrosis by blocking its N-terminal CC domain function. It blocks necrosis downstream of RIP3 activation. Necrosulfonamide has no effect on apoptosis induced by TNF-α plus Smac mimetic in non-RIP3-expressing Panc-1 cells, even at 5 μM concentration. The reason for the species specificity of necrosulfonamide is that the cysteine at residue 86 in human MLKL that is covalently modified by necrosulfonamide is replaced by a tryptophan residue in mouse MLKL(mixed lineage kinase domain-like protein)[2].
In vivo

Necrosulfonamide (NSA) is a small molecule that specifically inhibits necroptosis by targeting MLKL, the terminal executioner of necroptosis.

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    HT-29 cells

  • Concentrations

    1 μM

  • Incubation Time

    8 or 12 hrs

  • Method

    Necrosis inhibitors induce diverse effects on MLKL phosphorylation. HT-29 cells are treated with T/S/Z with or without necrosis inhibitors for 12 hr or 8 hr. The number of dead cells is determined by measuring released protease activity in culture medium. The whole-cell extracts are prepared and analyzed by western blotting. The final concentrations of 10 μM necrostatin-1 or 1 μM necrosulfonamide are used to block necrosis.
Animal Study:

[4]
  • Animal Models

    Male Wistar rats

  • Dosages

    1.65 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [ , , Biochim Biophys Acta, 2018, 1865(3):522-531 ]

Data from [ , , Biochem Biophys Res Commun, 2018, 503(3):1550-1556 ]

Selleck's Necrosulfonamide has been cited by 111 publications

Cytosolic cytochrome c represses ferroptosis [ Cell Metab, 2025, S1550-4131(25)00149-4] PubMed: 40233758
Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy [ Nat Commun, 2025, 16(1):4128] PubMed: 40319089
Androgen receptor inhibition sensitizes glioblastoma stem cells to temozolomide by the miR-1/miR-26a-1/miR-487b signature mediated WT1 and FOXA1 silencing [ Cell Death Discov, 2025, 11(1):248] PubMed: 40399259
O-GlcNAcylation of glutaminase isoform KGA inhibits ferroptosis through activation of glutaminolysis in hepatoblastoma [ Cell Death Discov, 2025, 11(1):160] PubMed: 40204725
Neuregulin-1 prevents death from a normally lethal respiratory viral infection [ PLoS Pathog, 2025, 21(4):e1013124] PubMed: 40267147
Sepsis-induced NET formation requires MYD88 but is independent of GSDMD and PAD4 [ FASEB J, 2025, 39(1):e70301] PubMed: 39777764
MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis [ Nature, 2024, 625(7995):585-592] PubMed: 38200309
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells [ Mol Cancer, 2024, 23(1):240] PubMed: 39465372
SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis [ Nat Commun, 2024, 15(1):7522] PubMed: 39215042
NR4A1 depletion inhibits colorectal cancer progression by promoting necroptosis via the RIG-I-like receptor pathway [ Cancer Lett, 2024, 585:216693] PubMed: 38301909

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.